



**Alliance for Clinical Trials in Oncology**  
**Loews Chicago O'Hare Hotel**  
**Friday, May 13, 2016**  
**1 pm – 5 pm**

## **Leukemia / Leukemia Correlative Sciences Committees Meeting Agenda**

Co-Chairs: Richard M. Stone, MD; John C. Byrd, MD  
Vice-Chairs: Guido Marcucci MD (LC), MD; Tom Shea, MD (LC)  
Wendy Stock, MD, PhD (LC/LCS)

### **Introduction**

Richard Stone MD (1:00-1:10)

### **Update: Leukemia Correlative Sciences**

John Byrd, MD (1:10-1:20)

### **Statistics and Data Management**

Sumithra Mandrekar PhD, et al (1:20 – 1:30)

### **Genomics of Decitabine Response in AML/MDS**

John Welch, MD, PhD (1:30-1:50)

### **Pharmacogenetics of Vincristine in Children and Adults**

William Evans, MD (1:50 -2:10)

### **CART Cells Coming to Cooperative Groups?**

Sarah Nikiforow (2:10-2:30)

Protocol Review				
Category	Study Title	Study Number	Study Chair	Presenter's Name
<b>Active</b>	Chemo +/- blinatumumab in middle aged adults with pre-B-ALL	E1910	M . Litzow M. Wieduwilt, (A)	M. Wieduwilt (2:30-2:35)
<b>In Development</b>	PH+ ALL working groups concepts, incl S0805 and C01701			K. Jamieson M. Wieduwilt (2:35-2:50)
<b>In development</b>	Aya chemo ± inotuzumab in younger adults with B cell ALL	A041501	D. DeAngelo	W. Stock (2:50-3:05)
<b>CTEP Approved</b>	Blinatumumamab plus POMP in PH- ALL, age >70	S1318	A.Advani M. Wieduwilt (A)	M. Wieduwilt (3:05-3:10)
<b>In Development</b>	Dual Ab rx of relapsed Ph-ALL		M. Wieduwilt	M. Wieduwilt (3:10-3:25)
<b>Active</b>	FCR v ibrutinib in younger CLL	E1910	T. Shanafelt J. Barrientos (A)	J. Barrientos (3:25-3:30)
<b>Active</b>	Ibrutinib v ibrutinib/rituximab v bendamustine/rituximab in older adults with untreated CLL	A041202	J. Woyach	J. Woyach (3:30-3:45)
<b>In Development</b>	Phase 3 study of FCR vs FCR + Ibrutinib for low risk IGHV mutated CLL < 70 yrs		J. Brown	J. Brown (3:45-4:00)
<b>Active</b>	Revlimid alone +/- Procrit in low or inter-1 risk MDS & symp anem	E2905	A. List	Notation Only
<b>In Development</b>	Potential MDS trial designs': MDS working group			T. Odenike, (4:00-4:15)
<b>In Development</b>	AML	3+7-based studies; etc	G. Marcucci G. Uy	G . Marcucci, G. Uy, R. Stone and others. (4:15-4:50)
<b>Active</b>	Transplant Initiatives Relevant to Alliance			T. Shea (4:50-5:00)